VALIRX PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.39 GBX | +2.73% |
|
-1.74% | -42.54% |
| Apr. 22 | Valirx plc Announces Directorate Changes | CI |
| Mar. 21 | ValiRx inks evaluation deal with Imperial College London for research | AN |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 4.37M 5.45M |
|---|---|---|---|---|---|
| Net income 2023 * | -2M -2.5M | Net income 2024 * | - | EV / Sales 2023 * | - |
| Net cash position 2023 * | 1.8M 2.25M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-0.02
x | P/E ratio 2024 * |
-
| Employees | 8 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 83.27% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.73% | ||
| 1 week | -1.74% | ||
| Current month | -4.51% | ||
| 1 month | -11.95% | ||
| 3 months | -32.87% | ||
| 6 months | -61.26% | ||
| Current year | -42.54% |
1 week
3.23
3.50
1 month
3.233.90
Current year
3.236.20
1 year
3.2315.00
3 years
3.2365.00
5 years
3.0073.00
10 years
3.009 575.00
| Managers | Title | Age | Since |
|---|---|---|---|
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
| Chief Tech/Sci/R&D Officer | - | 22-09-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Kevin Cox
CHM | Chairman | 65 | 20-06-25 |
| Director/Board Member | 57 | Feb. 28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3.39 | +2.73% | 59 014 |
| 24-04-25 | 3.3 | -4.35% | 607,805 |
| 24-04-24 | 3.45 | 0.00% | 49,024 |
| 24-04-23 | 3.45 | 0.00% | 1,232,579 |
| 24-04-22 | 3.45 | 0.00% | 483,843 |
Delayed Quote London S.E., April 26, 2024 at 10:18 am EDT
More quotes
ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.
Calendar
2024-09-24
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -42.54% | 5.46M | |
| -2.53% | 103B | |
| +0.44% | 95.71B | |
| +2.01% | 22.02B | |
| -16.92% | 20.9B | |
| -8.98% | 17.85B | |
| -42.83% | 16.21B | |
| -15.03% | 15.52B | |
| +3.26% | 13.86B | |
| +34.54% | 12.04B |
- Stock Market
- Equities
- VAL Stock
